or normal megakaryocyte count with normal erythroid and myeloid cells in bone marrow, and no history of drug intake or any previous illness such as systemic lupus erythematosus. All patients with acute ITP (platelet counts <30 × 10 9 /L) received HDMP (30 mg/kg per oral single dose a day) for 7 days. During the treatment blood pressure and pulse rate were monitored at least twice a day. Hemoglobin levels, white blood cell counts, red blood cell counts, and platelet counts were studied before and on the third, fifth, and eighth day of treatment. Before and after HDMP treatment (0 and eighth days), PT, PTT, fibrinogen, PC, PS, AT III, and the levels of FII, FV, FVII, FVIII, FIX, FX, FXI, and FXII were studied in all subjects. The results were compared with those of the control group.
Five milliliters of whole blood sample was collected in a 3.8% sodium citrate tube by venipuncture. The blood immediately centrifuged, and plasma samples were stored at -60°C until the analysis. Prothrombin time, PTT, FII, FV, FVII, FVIII, FIX, FX, FXI, FXII, PC, and PS were studied with a STA compact coagulometer (Diagnostica Stago Paris, France) using Diagnostica Stago kits. Informed consent was obtained from the parents.
The student t test; Mann-Whitney U, Chi square, and bivariate correlation tests were used for statistical analyses. Clinical parameters of the groups were compared with Anova. A p value less than 0.05 was considered as statistically significant.
RESULTS
Twenty-one children (13 males and eight females) with acute ITP were included in the study. The mean age of the patients was 6.14±3.45 years (1.5 to 14 years). The mean interval between the onset of the symptoms and the diagnosis was 12.8±5.3 days (3 to 21 days). Twenty-one healthy children (11 males and 10 females) were included as a control group. The mean age of the control subjects was 6.81±3.92 years (range, 2 to 15 years). There was no difference between the groups for age and gender (p>0.05).
Anemia was noted in 47% and 40% patients before and after HDMP treatment, respectively. Hemoglobin levels, red blood cells, and platelet counts were significantly increased after HDMP treatment (p<0.05) ( Table 1) .
Pre-treatment PC and PS levels in the patient group were significantly lower than the control groups (p<0.05). PS and PC levels were significantly improved after HDMP treatment in patient group. Post-treatment PS and PC levels were reached to the level of control groups. We found lower FV, FVII, and FX values in the patient group compared to the control groups on admission. While FV, FVII, FIX, and FX levels were increased, FII, FVIII, FXI, FXII levels were decreased after the HDMP treatment. However only FV levels showed a statistically significant change (p<0.05). We did not detect any difference in AT III and fibrinogen levels before and after treatment. The coagulation parameters of the infants at admission and after HDMP treatment are shown in Table 2 .
DISCUSSION
Hemostasis is regulated by components of the vessel wall and blood cells and by humoral coagulation factors. Under normal conditions, these components are involved in an active equilibrium through activation, propagation, and termination of the hemostatic pathways. In another way, hemostasis can be defined as the establishment of the precise equilibrium between procoagulant-antifibrinolytic and anticoagulant-profibrinolytic factors in the organism (7) . Although platelet count is accepted as the indicator of bleeding risk paradoxically, major clinical hemorrhages have not been reported in many children with serious thrombocytopenia associated with acute ITP. Intracranial hemorrhage incidence was reported as 0.1% in children having a platelet count of less than 20,000 during acute ITP attack (8) .
In our study, the levels of PC, PS, and vitamin K-dependent factors-FVII and FX-were found to be significantly lower when compared to levels in the control group. According to our knowledge, levels of PC and PS have not been reported in patients with acute ITP. Although this decrease can be attributed to liver dysfunction in the pretreatment period (9), we think that it may also be related to the factors other than liver insufficiency because liver function tests were normal in all patients. The deficiencies in PC and PS are accepted to be responsible in some cases of familial thrombosis. Acquired PC and PS deficiencies may be found in many cases such as liver diseases (10), disseminated intravascular coagulation (11), pulmonary emboli (12), acute respiratory distress syndrome (13), hemolytic-uremic syndrome (14) , thrombotic thrombocytopenic purpura (14) , hemolytic anemias (15), hematologic malignanicies (16) , and chemotherapeutic agents such as L-asparaginase and steroids. In particular, L-asparaginase was reported to cause PC and PS deficiencies in leukemic patients (3, 17) . Morever, PC and PS deficiencies were found to be induced by the decrease in the production by liver. Seifter and colleagues reported that antineoplastic drugs may cause decreases in the levels of coagulation proteins by affecting vitamin K absorption and metabolism (18) .
FV can be made available from two potential blood compartments: the plasma and platelets. Approximately 80% of the total blood FV circu- lates in plasma, whereas the remaining 20% is contained within platelet granules. The relative contribution of plasma versus platelet factor V to factor Va binding interactions in the prothrombinase complex are not clearly defined (19) . However, FV stored and released from platelets is of utmost importance in maintaining normal hemostasis. In our study, the cause of decreased FV level on admission may be related to decreased platelet counts. The studies related to the effects of HDMP treatment on hemostatic factors are too limited. Oner and colleagues found that PC, PS, and AT III levels were not changed following HDMP in 19 patients with ALL (3). Mall and colleagues reported a significant increase in AT III and PC levels after HDMP treatment in 42 patients with ALL (5). In another study, steroids in a standard dose were reported to cause increases in some hemostatic factors (4). Takaku and colleagues reported a patient with simultaneous development of factor V inhibitor and autoimmune thrombocytopenia, after the course of steroid therapy, FV level was markedly improved (20) . In our study, we found statistically significant increases in the levels of PC, PS, and FV following HDMP treatment. Although PS and PC levels and platelet counts were increased after treatment, there was not a statistically significant difference between them. Morever, there were increases in FVIII, FIX, and FX levels and decreases in FII FVIII, FXI, FXIII levels, but they were not statistically significant. There was no significant difference in postreatment PC, PS, FVII, and FX levels when compared to levels in the control group. Fibrinogen and AT III levels showed no significant changes by the treatment.
As a result, some changes in coagulation system associated with thrombocytopenia were observed in patients with acute ITP. The levels of natural anticoagulants such as PC and PS were decreased at the time of diagnosis and increased after HDMP treatment. These changes may be accepted as compansatory mechanisms to maintain hemostasis.
